Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

NCT04892472 is registered in ClinicalTrials.gov with NovoCure GmbH as lead sponsor.

NCT NCT04892472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04892472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
Lead sponsor
NovoCure GmbH
Phase
Phase 2
Overall status
Terminated
Start date
July 12, 2021
Completion date
January 10, 2025
Enrollment
15 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer